Imugene reports second complete response in azer-cel BTKi cohort

The article reports a near-term clinical update from a Phase 1b study of azer-cel in the Bruton Tyrosine Kinase inhibitor (BTKi) cohort, noting that a “first complete response” was reported one day earlier. No additional efficacy magnitude, safety details, or guidance are provided in the excerpt, so near-term market impact is likely limited without more specifics.

Analysis

The article reports a near-term clinical update from a Phase 1b study of azer-cel in the Bruton Tyrosine Kinase inhibitor (BTKi) cohort, noting that a “first complete response” was reported one day earlier. No additional efficacy magnitude, safety details, or guidance are provided in the excerpt, so near-term market impact is likely limited without more specifics.